Elisa Sensi

3.8k total citations · 1 hit paper
44 papers, 2.3k citations indexed

About

Elisa Sensi is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Elisa Sensi has authored 44 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 17 papers in Molecular Biology and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Elisa Sensi's work include Colorectal Cancer Treatments and Studies (16 papers), Lung Cancer Treatments and Mutations (11 papers) and BRCA gene mutations in cancer (8 papers). Elisa Sensi is often cited by papers focused on Colorectal Cancer Treatments and Studies (16 papers), Lung Cancer Treatments and Mutations (11 papers) and BRCA gene mutations in cancer (8 papers). Elisa Sensi collaborates with scholars based in Italy, United States and Germany. Elisa Sensi's co-authors include Cristiana Lupi, Gabriella Fontanini, Alfredo Falcone, Fotios Loupakis, Chiara Cremolini, Carlotta Antoniotti, Sara Lonardi, Cristina Granetto, Fulvio Basolo and Alberto Zaniboni and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and The Lancet Oncology.

In The Last Decade

Elisa Sensi

43 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

2015 733 citations Chiara Cremolini, Fotios Loupakis et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Elisa Sensi

Since Specialization

Citations

This map shows the geographic impact of Elisa Sensi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisa Sensi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisa Sensi more than expected).

Fields of papers citing papers by Elisa Sensi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisa Sensi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisa Sensi. The network helps show where Elisa Sensi may publish in the future.

Co-authorship network of co-authors of Elisa Sensi

This figure shows the co-authorship network connecting the top 25 collaborators of Elisa Sensi. A scholar is included among the top collaborators of Elisa Sensi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisa Sensi. Elisa Sensi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Feasibility of BRCA1/2 Testing of Formalin-Fixed and Paraffin-Embedded Pancreatic Tumor Samples: A Consecutive Clinical Series 2021 ·Diagnostics ·Rossella Bruno, Elisa Sensi, Cristiana Lupi, Mirella Giordano, (unknown), Caterina Vivaldi, Lorenzo Fornaro, Enrico Vasile, Daniela Campani, Gabriella Fontanini	4
2	Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation 2020 ·Journal of Molecular Diagnostics ·Riccardo Giannini, (unknown), Mirella Giordano, Clara Ugolini, Roberto Moretto, (unknown), Michele Leonardi, Elisa Sensi, Federica Morano, Filippo Pietrantonio, Chiara Cremolini, Alfredo Falcone, Gabriella Fontanini	11
3	The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy 2019 ·Frontiers in Oncology ·Antonio Matrone, Liborio Torregrossa, Elisa Sensi, Daniele Cappellani, (unknown), Raffaele Ciampi, Eleonora Molinaro, Clara Ugolini, (unknown), Luigi De Napoli, Francesco Latrofa, Gabriele Materazzi, Fulvio Basolo, Paolo Vitti, Rossella Elisei	2
4	Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months 2017 ·Experimental Hematology and Oncology ·Riccardo Marconcini, Luca Galli, Andrea Antonuzzo, (unknown), (unknown), Gabriella Fontanini, Elisa Sensi, Alfredo Falcone	28
5	EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center 2016 ·Oncology Reports ·Riccardo Giannini, Cristiana Lupi, Elisa Sensi, Greta Alì, Agnese Proietti, Laura Boldrini, Adele Servadio, Mirella Giordano, Elisabetta Macerola, Rossella Bruno, Nicla Borrelli, Antonio Chella, Franca Melfi, Marco Lucchi, Alessandro Ribechini, Enrico Vasile, Federico Cappuzzo, Alfredo Mussi, Gabriella Fontanini	13
6	Prophylactic Central Compartment Lymph Node Dissection in Papillary Thyroid Carcinoma: Clinical Implications Derived From the First Prospective Randomized Controlled Single Institution Study 2015 ·The Journal of Clinical Endocrinology & Metabolism ·David Viola, Gabriele Materazzi, Laura Valerio, Eleonora Molinaro, Laura Agate, Pinuccia Faviana, Veronica Seccia, Elisa Sensi, Cristina Romei, Paolo Piaggi, Liborio Torregrossa, Stefano Sellari‐Franceschini, Fulvio Basolo, Paolo Vitti, Rossella Elisei, Paolo Miccoli	221
7	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study breakdown → 2015 ·The Lancet Oncology ·Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti, Cristiana Lupi, Elisa Sensi, Sara Lonardi, Silvia Mezi, Gianluca Tomasello, Monica Ronzoni, Alberto Zaniboni, Giuseppe Tonini, Chiara Carlomagno, Giacomo Allegrini, Silvana Chiara, Mauro D’Amico, Cristina Granetto, Marina Elena Cazzaniga, Luca Boni, Gabriella Fontanini, Alfredo Falcone	733
8	KRAS and BRAF genotyping of synchronous colorectal carcinomas 2014 ·Oncology Letters ·Riccardo Giannini, Cristiana Lupi, Fotios Loupakis, Adele Servadio, Chiara Cremolini, Elisa Sensi, Massimo Chiarugi, Carlotta Antoniotti, Fulvio Basolo, Alfredo Falcone, Gabriella Fontanini	5
9	ALK Rearrangement in a Large Series of Consecutive Non–Small Cell Lung Cancers: Comparison Between a New Immunohistochemical Approach and Fluorescence In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment 2014 ·Archives of Pathology & Laboratory Medicine ·Greta Alì, Agnese Proietti, S Pelliccioni, Cristina Niccoli, Cristiana Lupi, Elisa Sensi, Riccardo Giannini, Nicla Borrelli, (unknown), Antonio Chella, Alessandro Ribechini, Federico Cappuzzo, Franca Melfi, Marco Lucchi, Alfredo Mussi, Gabriella Fontanini	60
10	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 2013 ·Targeted Oncology ·Fotios Loupakis, Chiara Cremolini, Anna Fioravanti, Paola Orlandi, Lisa Salvatore, Gianluca Masi, Marta Schirripa, Teresa Di Desidero, Carlotta Antoniotti, Bastianina Canu, Pinuccia Faviana, Elisa Sensi, Cristiana Lupi, Gabriella Fontanini, Fulvio Basolo, Antonello Di Paolo, Romano Danesi, Alfredo Falcone, Guido Bocci	29
11	FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO) 2013 ·Annals of Oncology ·Lorenzo Fornaro, Sara Lonardi, Gianluca Masi, Fotios Loupakis, Francesca Bergamo, Lisa Salvatore, Chiara Cremolini, Marta Schirripa, Caterina Vivaldi, Giuseppe Aprile, Alberto Zaniboni, Sergio Bracarda, Gabriella Fontanini, Elisa Sensi, Cristiana Lupi, (unknown), Vittorina Zagonel, Alfredo Falcone	76
12	FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer 2013 ·European Journal of Cancer ·Fotios Loupakis, Chiara Cremolini, Lisa Salvatore, Gianluca Masi, Elisa Sensi, Marta Schirripa, Angela Michelucci, E. Pfanner, I. Brunetti, Cristiana Lupi, Carlotta Antoniotti, Francesca Bergamo, Sara Lonardi, Vittorina Zagonel, Paolo Simi, Gabriella Fontanini, Alfredo Falcone	138
13	Folfoxiri plus Bevacizumab as first-line treatment of BRAF mutant metastatic colorectal cancer patients. 2012 ·Annals of Oncology ·Lisa Salvatore, Fotios Loupakis, Chiara Cremolini, Marta Schirripa, Gianluca Masi, Carlotta Antoniotti, Lorenzo Fornaro, Elisa Sensi, Cristiana Lupi, Francesca Bergamo, Sara Lonardi, (unknown), Gabriella Fontanini, Alfredo Falcone	4
14	Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial 2010 ·The Lancet Oncology ·Gianluca Masi, Fotios Loupakis, Lisa Salvatore, Lorenzo Fornaro, Chiara Cremolini, Samanta Cupini, A. Ciarlo, Francesca Del Monte, Enrico Cortesi, D. Amoroso, Cristina Granetto, Gabriella Fontanini, Elisa Sensi, Cristiana Lupi, M. Andreuccetti, Alfredo Falcone	190
15	Correlation between the BRAF V600E Mutation and Tumor Invasiveness in Papillary Thyroid Carcinomas Smaller than 20 Millimeters: Analysis of 1060 Cases 2010 ·The Journal of Clinical Endocrinology & Metabolism ·Fulvio Basolo, Liborio Torregrossa, Riccardo Giannini, Mario Miccoli, Cristiana Lupi, Elisa Sensi, Piero Berti, Rossella Elisei, Paolo Vitti, Angelo Baggiani, Paolo Miccoli	155
16	PALB2: a novel inactivating mutation in a Italian breast cancer family 2010 ·Familial Cancer ·(unknown), Elisa Sensi, Grazia Lombardi, Manuela Roncella, Generoso Bevilacqua, Maria A. Caligo	23
17	Genetic alterations in hereditary breast cancer 2004 ·Annals of Oncology ·Giovanna Cipollini, Stefania Tommasi, Angelo Paradiso, Paolo Aretini, (unknown), I. Brunetti, (unknown), Giovanni Lombardi, Francesco Schittulli, Elisa Sensi, Mariella Tancredi, Generoso Bevilacqua, Maria A. Caligo	42
18	Haplotype analysis of BRCA1 gene reveals a new gene rearrangement: characterization of a 19.9 KBP deletion 2004 ·European Journal of Human Genetics ·Mariella Tancredi, Elisa Sensi, Giovanna Cipollini, Paolo Aretini, Grazia Lombardi, Claudio Di Cristofano, Silvano Presciuttini, Generoso Bevilacqua, Maria A. Caligo	15
19	Clinicopathological Significance of GADD45 Gene Alterations in Human Familial Breast Carcinoma 2004 ·Breast Cancer Research and Treatment ·Elisa Sensi, Mariella Tancredi, Paolo Aretini, Giovanna Cipollini, Paola Collecchi, Antonio Giuseppe Naccarato, Paolo Viacava, Generoso Bevilacqua, Maria A. Caligo	5
20	Germline mutations of the BRCA1‐associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations 2002 ·Genes Chromosomes and Cancer ·Chiara Ghimenti, Elisa Sensi, Silvano Presciuttini, I. Brunetti, Pierfranco Conté, Generoso Bevilacqua, Maria A. Caligo	91

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact